الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
GIST is a rare tumor that represents approximately 1 to 2 percent of primary gastrointestinal (GI) cancers. Despite their rarity, GISTs are the most common mesenchymal, nonepithelial) neoplasms of the GI tract with annual incidence reported in the literature varies by region: 3.2–6.8 cases per million persons in the United States
Approximately, 65% of GIST originates from stomach and 30 % from jejunum & ileum, 4-5%in duodenum, 1-2% from appendix and colon, 1% from esophagus.
The aim of this work is to retrospectively analyze the epidemiological, clinicopathological features of GIST and its correlation with clinical outcome in the form of disease free survival, and to analyze treatment strategy and its side effects in the adjuvant settings after surgical resection of GIST in the period from January 2016 to December 2022.
This study is a retrospective study that included 40 patients diagnosed with GIST attending at sarcoma clinic at clinical oncology department at Ain Shams University hospital, in the period from start of January 2016 to December 2022.
The mainstay of treatment of GIST is surgical resection followed by adjuvant imatinib daily dose 400 mg for 3 years. The evolution of imatinib had improved disease free survival and became standard choice for adjuvant, locally advanced and metastatic settings, with generally well tolerated side effects during duration of treatment.
Conclusions and recommendations
The mainstay of treatment of GIST is surgical resection followed by adjuvant imatinib daily dose 400 mg for 3 years. The evolution of imatinib had improved disease free survival and became standard choice for adjuvant, locally advanced and metastatic settings, with generally well tolerated side effects during duration of treatment
Histopathological features as: site, size, risk stratification, mitotic index, ki67, PDGFRA mutation have distinct clinical behavior, response to treatment, and risk of recurrence, which highlights the importance of detection of these factors as predictive indicators for prognosis.
Late recurrence is not rare in GIST, which requires regular follow up for possibility of early detection and management.
For more accurate assessment of the population, it is advised to conduct multicenter studies with more than one center covering wider portion of population and discussing the management plans with other professionals at various facilities.